Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.
- Published In:
- Clinical and experimental immunology, 191(1), 96-106 (2018)
- Authors:
- Kusaka, S, Nishida, A, Takahashi, K, Bamba, S, Yasui, H, Kawahara, M, Inatomi, O, Sugimoto, M, Andoh, A
- Database ID:
- RPEP-03764
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03764APA
Kusaka, S; Nishida, A; Takahashi, K; Bamba, S; Yasui, H; Kawahara, M; Inatomi, O; Sugimoto, M; Andoh, A. (2018). Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.. Clinical and experimental immunology, 191(1), 96-106. https://doi.org/10.1111/cei.13047
MLA
Kusaka, S, et al. "Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.." Clinical and experimental immunology, 2018. https://doi.org/10.1111/cei.13047
RethinkPeptides
RethinkPeptides Research Database. "Expression of human cathelicidin peptide LL-37 in inflammato..." RPEP-03764. Retrieved from https://rethinkpeptides.com/research/kusaka-2018-expression-of-human-cathelicidin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.